bluebird bio (NASDAQ:BLUE) : Traders are bullish on bluebird bio (NASDAQ:BLUE) as it has outperformed the S&P 500 by a wide margin of 15.35% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 5.44%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 6.79% in the last 1 week, and is up 17.22% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock.
The company shares have dropped -70.26% from its 1 Year high price. On Jul 15, 2015, the shares registered one year high at $171.24 and the one year low was seen on May 12, 2016. The 50-Day Moving Average price is $43.33 and the 200 Day Moving Average price is recorded at $46.59.
The stock has recorded a 20-day Moving Average of 15.74% and the 50-Day Moving Average is 15.09%.
bluebird bio (NASDAQ:BLUE): On Fridays trading session , Opening price of the stock was $47.64 with an intraday high of $49.33. The bears continued to sell at higher levels and eventually sold the stock down to an intraday low of $47.5. However, the stock managed to close at $48.75, a loss of 0.16% for the day. On the previous day, the stock had closed at $48.83. The total traded volume of the day was 1,069,678 shares.
In an insider trading activity,The officer (Chief Medical Officer) of Bluebird Bio, Inc., Davidson David sold 1,000 shares at $40.11 on June 15, 2016. The Insider selling transaction had a total value worth of $40,110. The Insider information was disclosed with the Securities and Exchange Commission in a Form 4 filing.
bluebird bio, Inc. is a clinical-stage biotechnology company. The Company is focused on developing and commercializing products based on the transformative potential of gene therapy to treat patients with severe genetic diseases and cancer. The Companys products include Lenti-D, LentiGlobin and CAR T Cells. The Company is developing Lenti-D to treat patients with CCALD (Childhood cerebral adrenoleukodystrophy), the severe form of ALD (Adrenoleukodystrophy). The Company is conducting a Phase II/III clinical study of Lenti-D in the United States. The Company is developing LentiGlobin to treat patients with b-thalassemia and severe SCD (sickle cell disease). The Company is conducting a Phase I/II clinical study of LentiGlobin. It also initiated a second Phase I/II clinical study in the United States, Australia and Thailand for LentiGlobin. The Company is developing CAR T cell technology to deliver T cells engineered to kill the cancer.